Ilza Monteiro

ORCID: 0000-0002-9536-0564 · 8 papers in corpus · active 2007-2025

Study types

  • article 4
  • other 2
  • review 2

Condition tags

  • endometriosis 3
  • dysmenorrhea 2
  • adenomyosis 2
  • chronic_pelvic_pain 1
other 2025
Compounded hormonal pellets: a critical review of current evidence and risks
Revista da Associacao Medica Brasileira (1992) ·doi:10.1590/1806-9282.20250121
article 2016
The Use of Long Acting Reversible Contraceptives and the Relationship between Discontinuation Rates due to Menopause and to Female and Male Sterilizations
·doi:10.1055/s-0036-1583758

Introduction Women require effective contraception until they reach menopause. The long acting reversible contraceptives (LARC) and the depot-medroxyprogesterone acetate (DMPA, Depo-Provera®, Pfizer, Puurs, Belgium) are great options and ca…

article 2016
The Use of Long Acting Reversible Contraceptives and the Relationship between Discontinuation Rates due to Menopause and to Female and Male Sterilizations Uso de contraceptivos reversíveis de longa duração e a relação entre taxas de descontinuidade devido à menopausa e à esterilização de homens e mulheres

Introduction Women require effective contraception until they reach menopause. The long acting reversible contraceptives (LARC) and the depot-medroxyprogesterone acetate (DMPA, Depo-Provera®, Pfizer, Puurs, Belgium) are great options and ca…

other 2011
Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas
Contraception ·doi:10.1016/j.contraception.2011.05.012

BACKGROUND: Despite the high contraceptive efficacy and the additional noncontraceptive benefits of the levonorgestrel-releasing intrauterine system (LNG-IUS), concerns persist with respect to its use in nulligravidas. The objective of this…

article 2010
Treatment of heavy menstrual bleeding with a new combination of estradiol valerate and dienogest
·doi:10.2147/oajc.s7943

Abstract: The first combined oral contraceptive (OC) was launched in the US 50 years ago and was followed by another formulation introduced in Germany one year later. The most common estrogen component in current formulations is ethinylestr…

article 2009
Levonorgestrel intrauterine system and medroxyprogesterone acetate for treatment of heavy menstrual bleeding
·doi:10.1016/j.contraception.2009.05.069
review 2008
Levonorgestrel-releasing intrauterine system: uses and controversies
Expert review of medical devices ·doi:10.1586/17434440.5.4.437

This article provides a perspective on the use of the levonorgestrel-releasing intrauterine system as a contraceptive method and as therapy in different situations, as well as presenting the corresponding controversies and unresolved issues…

review 2007
Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea
Contraception ·doi:10.1016/j.contraception.2006.12.008

OBJECTIVES: This report is a review of the medical literature on the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in women with endometriosis, adenomyosis, cyclic pelvic pain and dysmenorrhea. MATERIAL AND METHODS: A r…